American Society of Clinical Oncology (ASCO)
Journal of Clinical Oncology (JCO) Podcast
The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO's flagship Journal of Clinical Oncology. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on the most impactful published findings. The Journal of Clinical Oncology Podcast is the trusted resource that empowers you to integrate cutting-edge evidence into clinical practice. The year's fellows interview authors and summarize the top Journal of Clinical Oncology articles in the series, JCO Article Insights.
Author
American Society of Clinical Oncology (ASCO)
Category
Podcast website
Latest episode
Jun 11, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
The SUCCEED Trial: Maintenance Ridaforolimus for Metastatic Soft- Tissue Sarcomas 30.05.2013 7:18
This podcast provides observations and commentary on the JCO article,"Results of an international randomized phase 3 trial of the mTOR inhibitor, ridaforolimus, versus placebo to control metastatic sarcomas in patients following benefit from prior chemotherapy" by authors George Demetri, et al.
Who Needs What Therapy? The Elusive Search for Predictive Markers 06.05.2013 8:56
Loss of PTEN expression did not predict resistance to trastuzumab in early stage HER2 positive breast cancer in the large US cooperative group phase III trial N9831.
Micro RNAs and Other Molecular Markers in AML Therapeutics 06.05.2013 8:56
This podcast describes the current and future use of molecular testing, including micro RNA expression, in the management of AML.
Neuroanatomic and Neuropsychological Outcomes in Adults after Treatment for Childhood Acute Lymphoblastic Leukemia 15.04.2013 9:25
This podcast focuses on emerging concerns about adult outcomes in survivors of acute lymphoblastic leukemia treated in childhood and adolescence in the context of the report by Zeller and colleagues documenting neuroanatomical and neuropsychological impairment in a large sample of adults treated successfully for ALL without cranial radiation therapy and healthy controls.
HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers 15.04.2013 10:33
This Podcast reviews the results of the analysis conducted by Metzger-Filho et al. regarding the benefit of trastuzumab for patients with invasive lobular breast cancer treated on the Herceptin Adjuvant Trial (HERA) and provides perspective regarding the clinical significance of these findings.
New Evidence of the Clinical Significance of Cigarette Smoking by Colon Cancer Patients 01.04.2013 10:33
This podcast summarizes findings regarding cigarette smoking and disease-free survival in a Phase III adjuvant colon cancer trial.
Radiotherapy for Pediatric Hodgkin Lymphoma: Are We Ready To Say Goodbye? 18.03.2013 11:08
Response after early chemotherapy cycles might identify patients who could safely forgo consolidation with radiotherapy.
Minimal-Intensity Conditioning: A Decade Later 11.03.2013 15:41
This podcast reflects on the outcome of minimal intensity conditioning in over 1000 recipients of sibling and unrelated donor transplant.
Evolution of Concurrent Chemoradiation Treatment Approaches in Head and Neck Cancer 05.03.2013 8:56
This podcast provides commentary and observations on the long term results summary of RTOG 91-11 in which concurrent chemoradiation was shown to provide superior outcome over induction chemotherapy or radiation alone to achieve larynx preservation and locoregional tumor control.
Off-Label Cancer Therapy Use: How Much is Too Much? 19.02.2013 9:57
This podcast reviews findings on the prevalence of off-label cancer therapy use and the estimated costs associated with it.
Caring For Patients With Transformed Follicular Lymphoma 12.02.2013 7:23
If transplantation is selected as the treatment approach, the net effect is likely to be similar with allogeneic or autologous transplantation with the higher early mortality rate in the allogeneic patients offset by a higher relapse rate in the autologous patients.
Outpatient Therapy for Fever and Neutropenia is Safe But Implementation is the Key 28.01.2013 5:17
The fluoroquinolone class of antibiotics is a major target for antimicrobial stewardship programs, and the conservation of their effectiveness is important.
Outcomes in Cancer Survivors Who Develop Second Malignant Neoplasms 22.01.2013 11:16
This podcast provides perspective on findings in a large population-based evaluation of overall survival and cancer-specific survival in patients with CLL who develop a second primary cancer.
Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine 22.01.2013 9:33
One third of gastric cancers harbor genetic or epigenetic alterations in the CDH1 gene, and those with structural changes have a poorer prognosis; gastric tumor profiling for oncogenic amplifications and mutations may identify targets for personalized therapeutics.
Reflections on "Cancer Survivorship": Evolution, Utility, and Acceptability 03.01.2013 7:12
This podcast considers the evolution, utility, and acceptability of the terms 'cancer survivor' and 'cancer survivorship' and comments on a recent article in JCO that addresses the extent to which such labels matter to survivors and others affected by this disease.
Estimating the Risk for Contralateral Breast Cancer as a Guide for Surgical Treatment 03.01.2013 7:22
This podcast discusses approaches to risk assessment of contralateral breast cancer and factors which predict the risk.
Revisiting Combination TACE-RFA Treatment for HCC 03.01.2013 13:07
Amongst several different liver directed therapy approaches, chemoembolization (called TACE) and radiofrequency ablation (called RFA) are most commonly used worldwide. However, the efficacy of TACE and RFA remains limited.
Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma 19.12.2012 7:27
A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.
Successful Non-Intensive Bridging of MDS Patients Towards Allografting 19.12.2012 5:39
This podcast discusses therapeutic options for MDS patients including azacytidine and allogeneic stem cell transplantation.
Using a Video Decision Support Tool for CPR Decision-Making 11.12.2012 5:39
This video support tool describing CPR lets patients make much better informed decisions about the use of CPR. Physicians often feel that CPR will not be of help to patients but nevertheless feel obligated to offer it or not withhold it. This video support tool describing CPR might enable patients to make much better informed decisions about the use of CPR. Letting patients view this 6 minute vide...
Radioimmunotherapy for the Initial Treatment of Follicular Lymphoma 11.12.2012 10:53
Radioimmunotherapy alone or in sequential combination with chemotherapy is effective initial treatment for follicular lymphoma, though comparable (and not superior) to other management options for this population.
Management of Metastases to the Brain: A Therapeutic Conundrum 03.12.2012 9:48
Whole-brain radiation therapy of metastases to the brain is not innocuous - it is associated with decrements in health-related quality of life. It is still unknown if the potential benefits outweigh the impact of the side effects.
Understanding the Role of MET Kinase in Cancer Therapy 03.12.2012 8:32
This is a commentary on the role of MET in cancer using Choueri et al as an example of rationale therapeutics and translational research.
AIDS Related Lymphomas - More Options and More Questions 19.11.2012 10:12
A discussion of treatment approaches for newly diagnosed aggressive AIDS-related lymphomas
Long Term Follow-up of NSABP B-31: How Well Can We Predict Cardiac Toxicity with Trastuzumab? 16.11.2012 16:40
Seven year follow up of B-31 demonstrates a striking and reassuring lack of longer-term cardiac events.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.